Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer

Xuefei Wang,Junjie Zhao,Zhenbin Shen,Mark Fairweather,Peter C. Enzinger,Yihong Sun,Jiping Wang

DOI: https://doi.org/10.1016/j.jss.2020.05.058

2020-01-01

Abstract:Background: The necessity of extensive lymph node (LN) dissection/examination and adjuvant therapy for patients with early gastric cancer (EGC, Tis-T1, any N) remains controversial. We aim to refine treatment recommendations for patients with EGC through a reflective analysis for the survival gap between Eastern and Western countries. Methods: EGC patients diagnosed between 2004 and 2014 were identified from the National Cancer Database (NCDB) and a large medical center in China. Adequate LN yield was defined as >= 25 LNs examined. Results: In the US cohort, 14.4% of (1104/7641) patients with EGC had >= 25 LNs examined. The 5-y overall survival (OS) was significantly better than those with < 25 LNs (78.9% versus 68.5%, P < 0.001). Examination of >= 25 LNs was an independent predictor of better OS after adjusting all known prognostic factors. Patients with >= 25 LNs examined had significantly higher chance of having LN-positive disease compared to patients with < 25 LNs (14.9% versus 10.7%, P < 0.001). A similar stage migration phenomenon was observed in Chinese cohort (LN positive: 25.2% versus 18.4% in >= 25 LNs and < 25 LNs examined group, respectively, P 1/4 0.02). In the US cohort, adjuvant therapy was associated with a significant survival benefit for LN-positive patients (5-y OS: 71.0% versus 43.0% for with/without adjuvant therapy, respectively, P < 0.001) but not in LN-negative patients (5-y OS: 71.2% versus 71.5%, P = 0.90). Conclusions: Adequate lymphadenectomy and LN examination are critical components of EGC management. Adjuvant therapy should be strongly encouraged for all EGC patients with LN-positive disease in the United States. (C) 2020 Elsevier Inc. All rights reserved.